NICE technology appraisal

for Hybrid Closed Loop systems

NICE now recommends Hybrid Closed Loop (HCL) systems for selected people with type 1 diabetes1

Woman using the Ypsomed insulin pump with the FreeStyle Libre 3 system
Woman using the Ypsomed insulin pump with the FreeStyle Libre 3 system
Woman using the Ypsomed insulin pump with the FreeStyle Libre 3 system

The new NICE technology appraisal recommendation means more type 1 patients qualify for a Hybrid Closed (HCL) compatible CGM system

NICE guidelines for HCL

NICE recommends HCL1 as an option for managing blood glucose levels in type 1 diabetes in:

  • Adults with HbA1c ≥7.5% (58mmol/mol), or who have disabling hypoglycaemic episodes despite continuous subcutaneous insulin (CSII), real-time continuous glucose monitoring (rtCGM) or intermittently scanned CGM (isCGM)

  • Children and young people

  • Those who are pregnant or are planning pregnancy

HCP with Hybrid Closed Loop system HCP with Hybrid Closed Loop system HCP with Hybrid Closed Loop system

Benefits of HCL systems1,2

Improved HbA1c

Increased Time in Range

Reduced hypoglycemia

Reduced diabetes distress

Improved quality of life

 FreeStyle Libre Systems & Partnerships

Accurate, minute-to-minute glucose data combined with automated insulin delivery

Connected insulin pumps can prevent low and high glucose levels by automatically adjusting insulin delivery based on FreeStyle Libre 2 Plus sensor or FreeStyle Libre 3 sensor readings.

FreeStyle Libre 2 Plus sensor lasts 15 days

The FreeStyle Libre 3 sensor is authorised to work with the mylife Loop automated insulin delivery system, including the mylife CamAPS FX app and mylife YpsoPump insulin pump.3

The mylife Loop system provides easy, automatic adjustment of insulin delivery based on FreeStyle Libre 3 sensor readings to prevent low and high glucose levels.

FreeStyle Libre 3 and Ypsomed
FreeStyle Libre 2 Plus sensor lasts 15 days

Our 15-day sensor and Omnipod 5 Automated Insulin Delivery System (AID) create one easy, integrated experience for your patients

Wide availability of the FreeStyle Libre 2 Plus sensor is not expected until June 2024, once GP Prescribing systems have been updated

OmniPod & FreeStyle Libre 2 Plus sensor Pod shown without the necessary adhesive.

References & Disclaimers

FreeStyle, Libre, and related brand marks are marks of Abbott. Mylife and YpsoPump are registered trademarks of Ypsomed AG. CamAPS is a registered trademark of CamDiab Ltd. Omnipod and the Omnipod logo are registered trademarks of Insulet Corporation and used with permission. Other trademarks are the property of their respective owners. 

1. NICE technology appraisal guidance TA943 (2023). Available at https://www.nice.org.uk/guidance/ta943. Accessed April 2024.

2. Crabtree TSJ, Griffin TP, Yap YW, Narendran P, Gallen G, Furlong N, Cranston I, Chakera A, Philbey C, Karamat MA, Saraf S, Kamaruddin S, Gurnell E, Chapman A, Hussain S, Elliott J, Leelarathna L, Ryder REJ, Hammond P, Lumb A, Choudhary P, Wilmot EG; ABCD Closed-Loop Audit Contributors. Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study. Diabetes Care. 2023 Oct 1;46(10):1831-1838. doi: 10.2337/dc23-0635. PMID: 37566697; PMCID: PMC10516256.

3. FreeStyle Libre 3 sensor is authorised to work with the mylife Loop automated insulin delivery system, including the mylife CamAPS FX app and mylife YpsoPump insulin pump. For use of FreeStyle Libre 3 sensor with the mylife Loop, refer to the labeling provided with the mylife CamAPS FX app.

Loading...